Navigation Links
FDLI's Food and Drug Policy Forum Examines European GMO Rules
Date:1/25/2011

WASHINGTON, Jan. 25, 2011 /PRNewswire-USNewswire/ -- The second issue of FDLI's Food and Drug Policy Forum (Volume 1, Number 2), to be published January 26, 2011, focuses on the increasingly important issue of genetically modified organisms (GMOs).

In the article published on the Food and Drug Law Institute's website (www.fdli.org), Ross H. Pifer, Director, and Richard J. Lupinsky, Jr., Research Fellow at the Agricultural Law Resource and Reference Center at Penn State University's Dickinson School of Law, make recommendations on this emerging international food and drug issue: "Should the European Union Proceed with the Implementation of New GMO Rules?"

Pifer and Lupinsky conclude that new GMO rules in the European Union need additional clarity to create a proper framework for the approval of genetically modified products, explaining that "stakeholders on all sides believe that the proposal actually will increase legal uncertainty and create more chaos surrounding both the decision-making process and labeling standards." The authors specifically recommend that the European Commission modify the major standard expressed in proposed Article 26b(a), a European Union Member States' Directive, to better explain the specific bases upon which Member States can restrict or prohibit cultivation of particular GMOs, integrate and harmonize the content of Article 26b with the Safeguard Clause, and maintain uniform standards of labeling for GMOs.

FDLI's Food and Drug Policy Forum is a twice-a-month, peer-reviewed, digital publication on current food and drug policy topics. Posed in the form of a question, each issue provides subscribers and purchasers with pertinent background information, relevant research, a discussion of central issues, relevant resources and policy recommendations. The views, opinions and statements expressed in the Policy Forum are those of the authors. The Food and Drug Law Institute neither contributes to nor endorses Policy Forum articles. As a nonprofit 501 (c) (3) organization, FDLI does not engage in advocacy activities.

FDLI, founded in 1949, is a non-profit organization that provides a marketplace for discussing food and drug law issues through conferences, publications and member interaction. FDLI's scope includes food, drugs, animal drugs, biologics, cosmetics, diagnostics, dietary supplements, medical devices and tobacco.

FDLI members receive the Policy Forum as a benefit of their membership. Non-members may subscribe to the Forum for a fee.


'/>"/>
SOURCE Food and Drug Law Institute
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Change in Medicare Wheelchair Policy May Prevent Texas Beneficiaries from Receiving Mobility Assistance Starting January
2. Rural Wheelchair Patients Will Be Hit Hard by Power Wheelchair Rental Policy; Providers, Advocates Ask Congress for a Delay
3. K-V Pharmaceutical Company Announces Reliance on Financial Distress Exception to NYSEs Shareholder Approval Policy
4. Congress Urged to Delay New Medicare Wheelchair Rental Policy
5. Medicare Policy Changes Will Make it More Difficult for Nevada Beneficiaries to Obtain Power Wheelchairs
6. Utahs Seniors and People with Disabilities Will Feel Impact of Medicare Policy Changes that Restrict Access to Power Wheelchairs
7. American College of Surgeons Health Policy Research Institute Releases Surgery Workforce Atlas That Shows Surgeon Shortage Across the U.S.
8. Physician Outraged by Medicare Power Wheelchair Documentation Policy
9. NORD Calls for Statement of Policy on Orphan Drug Development
10. Reportlinker Adds Latin American Pharmaceutical Market Outlook to 2014: Policy environment, market analysis, forecasts and growth opportunities
11. Stryker Modifies Its Dividend Policy and Declares Transition Dividend
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/29/2016)... India , April 29, 2016 ... the life science laboratory due to the growing demands ... by advance technology, contemporary automated systems are already adept ... performed by slow, tedious and manual labor. Instrumentation continues ... were not even conceivable just a few years ago. ...
(Date:4/28/2016)... , April 28, 2016  While Abbott,s announced ... the company,s valve repair and stent business, healthcare ... places Abbott more firmly into patient monitoring.  Kalorama ... fastest growing device areas, with double-digit growth expected ... report,  Advanced Remote Patient Monitoring . ...
(Date:4/28/2016)... , April 28, 2016  Marking its ... accessible breast and ovarian cancer risk test, ... analyzing 30 genes that highly impact the most ... Available today, the Color Test analyzes hereditary cancer ... stomach, and uterine cancers. The Color Test is ...
Breaking Medicine Technology:
(Date:5/3/2016)... ... , ... Cosmetic surgeon Dr. Mark Youssef first introduced Voluma® to his ... his menu of services to give his patients as many options as possible in ... improving his approach to ensure he stays at the forefront of the most modern ...
(Date:5/3/2016)... ... May 03, 2016 , ... ... been selected by Tidelands Health, a three hospital system in South Carolina, to ... on the lookout for technology that enhances communication, drives workflow efficiencies and improves ...
(Date:5/3/2016)... Texas (PRWEB) , ... May 03, 2016 , ... Park ... that live in or adjacent to the 75204, 75205, 75206, 75209, 75219, 75220, 75225, ... Lawn/Uptown, Greenway Parks, Bluffview, Midway Hollow, North Dallas, Plano, Preston Hollow and Park Cities ...
(Date:5/3/2016)... ... May 03, 2016 , ... Octo Consulting ... and digital consulting services to the federal government, has been awarded a $9.9 ... Indefinite Quantity (ID/IQ) contract in support of the U.S. Army Program Executive Office ...
(Date:5/3/2016)... California (PRWEB) , ... May ... ... leading provider of Microsoft secure remote access connectivity solutions, today announced the ... platform for Microsoft DirectAccess. The new Celestix SecureAccess release will enable organizations ...
Breaking Medicine News(10 mins):